메뉴 건너뛰기




Volumn 19, Issue 5, 2013, Pages 969-976

Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

EID: 84874912760     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2502     Document Type: Article
Times cited : (47)

References (47)
  • 1
    • 0036433245 scopus 로고    scopus 로고
    • European Organisation for Research and Treatment of Cancer Data Center: Evaluation of response: New and standard criteria
    • Therasse P. European Organisation for Research and Treatment of Cancer Data Center: evaluation of response: new and standard criteria. Ann Oncol 2002;13Suppl 4: 127-9.
    • (2002) Ann Oncol , vol.13 , Issue.SUPPL. 4 , pp. 127-129
    • Therasse, P.1
  • 2
    • 77951642723 scopus 로고    scopus 로고
    • Overall survival and post-progression survival in advanced breast cancer: A review of recent randomized clinical trials
    • Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010;28: 1958-62.
    • (2010) J Clin Oncol , vol.28 , pp. 1958-1962
    • Saad, E.D.1    Katz, A.2    Buyse, M.3
  • 3
    • 42949145995 scopus 로고    scopus 로고
    • Evaluation of tumor response, disease control, progression- free survival, and time to progression as potential surrogate end points in metastatic breast cancer
    • Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, et al. Evaluation of tumor response, disease control, progression- free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26: 1987-92.
    • (2008) J Clin Oncol , vol.26 , pp. 1987-1992
    • Burzykowski, T.1    Buyse, M.2    Piccart-Gebhart, M.J.3    Sledge, G.4    Carmichael, J.5    Luck, H.J.6
  • 4
    • 55949094052 scopus 로고    scopus 로고
    • Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer
    • Sherrill B, Amonkar M, Wu Y, Hirst C, Stein S, Walker M, et al. Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008;99: 1572-8.
    • (2008) Br J Cancer , vol.99 , pp. 1572-1578
    • Sherrill, B.1    Amonkar, M.2    Wu, Y.3    Hirst, C.4    Stein, S.5    Walker, M.6
  • 7
    • 35649022759 scopus 로고    scopus 로고
    • Surrogate end points for median overall survival in metastatic colorectal cancer: Literaturebased analysis from 39 randomized controlled trials of first-line chemotherapy
    • Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literaturebased analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25: 4562-8.
    • (2007) J Clin Oncol , vol.25 , pp. 4562-4568
    • Tang, P.A.1    Bentzen, S.M.2    Chen, E.X.3    Siu, L.L.4
  • 8
    • 0035371228 scopus 로고    scopus 로고
    • Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma
    • Louvet C, de Gramont A, Tournigand C, Artru P, Maindrault-Goebel F, Krulik M. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001;91: 2033-8.
    • (2001) Cancer , vol.91 , pp. 2033-2038
    • Louvet, C.1    De Gramont, A.2    Tournigand, C.3    Artru, P.4    Maindrault-Goebel, F.5    Krulik, M.6
  • 10
    • 78149250536 scopus 로고    scopus 로고
    • Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study
    • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-705.
    • (2010) J Clin Oncol , vol.28 , pp. 4697-4705
    • Douillard, J.Y.1    Siena, S.2    Cassidy, J.3    Tabernero, J.4    Burkes, R.5    Barugel, M.6
  • 11
    • 78149239651 scopus 로고    scopus 로고
    • Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
    • Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28: 4706-13.
    • (2010) J Clin Oncol , vol.28 , pp. 4706-4713
    • Peeters, M.1    Price, T.J.2    Cervantes, A.3    Sobrero, A.F.4    Ducreux, M.5    Hotko, Y.6
  • 12
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEngl J Med 2004;350: 2335-42.
    • (2004) NEngl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3    Cartwright, T.4    Hainsworth, J.5    Heim, W.6
  • 13
    • 60649088752 scopus 로고    scopus 로고
    • Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer
    • Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-Jones R, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009;20: 244-50.
    • (2009) Ann Oncol , vol.20 , pp. 244-250
    • Cunningham, D.1    Sirohi, B.2    Pluzanska, A.3    Utracka-Hutka, B.4    Zaluski, J.5    Glynne-Jones, R.6
  • 14
    • 34249000361 scopus 로고    scopus 로고
    • Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest
    • Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007;25: 1670-6.
    • (2007) J Clin Oncol , vol.25 , pp. 1670-1676
    • Falcone, A.1    Ricci, S.2    Brunetti, I.3    Pfanner, E.4    Allegrini, G.5    Barbara, C.6
  • 15
    • 0024520844 scopus 로고
    • Surrogate endpoints in clinical trials: Definition and operational criteria
    • Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8: 431-40.
    • (1989) Stat Med , vol.8 , pp. 431-440
    • Prentice, R.L.1
  • 16
    • 0026573094 scopus 로고
    • Statistical validation of intermediate endpoints for chronic diseases
    • Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11: 167-78.
    • (1992) Stat Med , vol.11 , pp. 167-178
    • Freedman, L.S.1    Graubard, B.I.2    Schatzkin, A.3
  • 17
    • 0001863948 scopus 로고    scopus 로고
    • The validation of surrogate endpoints in meta-analyses of randomized experiments
    • Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000;1: 49-67.
    • (2000) Biostatistics , vol.1 , pp. 49-67
    • Buyse, M.1    Molenberghs, G.2    Burzykowski, T.3    Renard, D.4    Geys, H.5
  • 18
    • 60549103258 scopus 로고    scopus 로고
    • Randomized study of weekly irinotecan plus highdose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
    • Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, et al. Randomized study of weekly irinotecan plus highdose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 2009;20: 251-7.
    • (2009) Ann Oncol , vol.20 , pp. 251-257
    • Aranda, E.1    Valladares, M.2    Martinez-Villacampa, M.3    Benavides, M.4    Gomez, A.5    Massutti, B.6
  • 19
    • 1342290189 scopus 로고    scopus 로고
    • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
    • Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22: 229-37.
    • (2004) J Clin Oncol , vol.22 , pp. 229-237
    • Tournigand, C.1    Andre, T.2    Achille, E.3    Lledo, G.4    Flesh, M.5    Mery-Mignard, D.6
  • 20
    • 0033989203 scopus 로고    scopus 로고
    • Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer
    • Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18: 136-47.
    • (2000) J Clin Oncol , vol.18 , pp. 136-147
    • Giacchetti, S.1    Perpoint, B.2    Zidani, R.3    Le Bail, N.4    Faggiuolo, R.5    Focan, C.6
  • 21
    • 0033874892 scopus 로고    scopus 로고
    • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    • de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18: 2938-47.
    • (2000) J Clin Oncol , vol.18 , pp. 2938-2947
    • De Gramont, A.1    Figer, A.2    Seymour, M.3    Homerin, M.4    Hmissi, A.5    Cassidy, J.6
  • 22
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26: 1626-34.
    • (2008) J Clin Oncol , vol.26 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3    Van Cutsem, E.4    Siena, S.5    Freeman, D.J.6
  • 23
    • 80053467288 scopus 로고    scopus 로고
    • Progressionfree survival as a primary endpoint in clinical trials of metastatic colorectal cancer
    • Gill S, Berry S, Biagi J, Butts C, Buyse M, Chen E, et al. Progressionfree survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol. 2011;18 Suppl 2):S5-10.
    • (2011) Curr Oncol. , vol.18 , Issue.SUPPL. 2
    • Gill, S.1    Berry, S.2    Biagi, J.3    Butts, C.4    Buyse, M.5    Chen, E.6
  • 24
    • 33644834827 scopus 로고    scopus 로고
    • Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
    • Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23: 8664-70.
    • (2005) J Clin Oncol , vol.23 , pp. 8664-8670
    • Sargent, D.J.1    Wieand, H.S.2    Haller, D.G.3    Gray, R.4    Benedetti, J.K.5    Buyse, M.6
  • 25
    • 80755155711 scopus 로고    scopus 로고
    • Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: Evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an Aide et Recherche en Cancerologie Digestive Group Study
    • Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol 2011;29: 4199-204.
    • (2011) J Clin Oncol , vol.29 , pp. 4199-4204
    • Chibaudel, B.1    Bonnetain, F.2    Shi, Q.3    Buyse, M.4    Tournigand, C.5    Sargent, D.J.6
  • 26
    • 17744418861 scopus 로고    scopus 로고
    • Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
    • Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21: 3721-8.
    • (2003) J Clin Oncol , vol.21 , pp. 3721-3728
    • Kohne, C.H.1    Wils, J.2    Lorenz, M.3    Schoffski, P.4    Voigtmann, R.5    Bokemeyer, C.6
  • 27
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, WongR, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26: 2013-9.
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3    Scheithauer, W.4    Figer, A.5    Wong, R.6
  • 28
    • 79959280313 scopus 로고    scopus 로고
    • Overall survival as the outcome for randomized clinical trials with effective subsequent therapies
    • Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 2011;29: 2439-42.
    • (2011) J Clin Oncol , vol.29 , pp. 2439-2442
    • Korn, E.L.1    Freidlin, B.2    Abrams, J.S.3
  • 29
    • 84886720022 scopus 로고    scopus 로고
    • Progression-free survival as a surrogate endpoint for median overall survival in mCRC: Literature-based analysis from 50 randomized first-line trials
    • Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, et al. Progression-free survival as a surrogate endpoint for median overall survival in mCRC: literature-based analysis from 50 randomized first-line trials. Clin Cancer Res 2012;13: 13.
    • (2012) Clin Cancer Res , vol.13 , pp. 13
    • Giessen, C.1    Laubender, R.P.2    Ankerst, D.P.3    Stintzing, S.4    Modest, D.P.5    Mansmann, U.6
  • 30
    • 36849069358 scopus 로고    scopus 로고
    • Toward progression-free survival as a primary end point in advanced colorectal cancer
    • Yothers G. Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 2007;25: 5153-4.
    • (2007) J Clin Oncol , vol.25 , pp. 5153-5154
    • Yothers, G.1
  • 31
    • 77949321968 scopus 로고    scopus 로고
    • Progression-free survival as surrogate and as true end point: Insights from the breast and colorectal cancer literature
    • Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21: 7-12.
    • (2010) Ann Oncol , vol.21 , pp. 7-12
    • Saad, E.D.1    Katz, A.2    Hoff, P.M.3    Buyse, M.4
  • 32
    • 0034727063 scopus 로고    scopus 로고
    • Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
    • Irinotecan Study Group
    • Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343: 905-14.
    • (2000) N Engl J Med , vol.343 , pp. 905-914
    • Saltz, L.B.1    Cox, J.V.2    Blanke, C.3    Rosen, L.S.4    Fehrenbacher, L.5    Moore, M.J.6
  • 33
    • 0036227995 scopus 로고    scopus 로고
    • A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
    • Blanke CD, Shultz J, Cox J, Modiano M, Isaacs R, Kasimis B, et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol 2002;13: 87-91.
    • (2002) Ann Oncol , vol.13 , pp. 87-91
    • Blanke, C.D.1    Shultz, J.2    Cox, J.3    Modiano, M.4    Isaacs, R.5    Kasimis, B.6
  • 34
    • 0036231984 scopus 로고    scopus 로고
    • Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: Final results of a randomised European study
    • Punt CJ, Keizer HJ, Douma J, Skovsgaard T, Schuller J, Muller EW, et al. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 2002;13: 81-6.
    • (2002) Ann Oncol , vol.13 , pp. 81-86
    • Punt, C.J.1    Keizer, H.J.2    Douma, J.3    Skovsgaard, T.4    Schuller, J.5    Muller, E.W.6
  • 35
    • 0037087668 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer
    • Schilsky RL, Levin J, West WH, Wong A, Colwell B, Thirlwell MP, et al. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. J Clin Oncol 2002;20: 1519-26.
    • (2002) J Clin Oncol , vol.20 , pp. 1519-1526
    • Schilsky, R.L.1    Levin, J.2    West, W.H.3    Wong, A.4    Colwell, B.5    Thirlwell, M.P.6
  • 36
    • 24644432555 scopus 로고    scopus 로고
    • Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
    • Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23: 4856-65.
    • (2005) J Clin Oncol , vol.23 , pp. 4856-4865
    • Kohne, C.H.1    Van Cutsem, E.2    Wils, J.3    Bokemeyer, C.4    El-Serafi, M.5    Lutz, M.P.6
  • 37
    • 34948857445 scopus 로고    scopus 로고
    • Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO Colorectal Study Group
    • Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25: 4217-23.
    • (2007) J Clin Oncol , vol.25 , pp. 4217-4223
    • Porschen, R.1    Arkenau, H.T.2    Kubicka, S.3    Greil, R.4    Seufferlein, T.5    Freier, W.6
  • 38
    • 42949150908 scopus 로고    scopus 로고
    • Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    • Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26: 2006-12.
    • (2008) J Clin Oncol. , vol.26 , pp. 2006-2012
    • Cassidy, J.1    Clarke, S.2    Diaz-Rubio, E.3    Scheithauer, W.4    Figer, A.5    Wong, R.6
  • 39
    • 53049092394 scopus 로고    scopus 로고
    • Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study
    • Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008;19: 1720-6.
    • (2008) Ann Oncol , vol.19 , pp. 1720-1726
    • Rothenberg, M.L.1    Cox, J.V.2    Butts, C.3    Navarro, M.4    Bang, Y.J.5    Goel, R.6
  • 40
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25: 1539-44.
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6
  • 41
    • 44249111440 scopus 로고    scopus 로고
    • EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
    • Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26: 2311-9.
    • (2008) J Clin Oncol , vol.26 , pp. 2311-2319
    • Sobrero, A.F.1    Maurel, J.2    Fehrenbacher, L.3    Scheithauer, W.4    Abubakr, Y.A.5    Lutz, M.P.6
  • 42
    • 59949102930 scopus 로고    scopus 로고
    • Et al.Arandomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    • Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al.Arandomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27: 672-80.
    • (2009) J Clin Oncol , vol.27 , pp. 672-680
    • Hecht, J.R.1    Mitchell, E.2    Chidiac, T.3    Scroggin, C.4    Hagenstad, C.5    Spigel, D.6
  • 44
    • 80053243066 scopus 로고    scopus 로고
    • Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: The effect of infusional 5-FU or capecitabine on the outcomes of the MRCCOIN trial in advanced colorectal cancer (ACRC)
    • July 13-20; Orlando, FL, Abstract nr 402
    • Maughan TS, Adams R, Smith CG, Seymour MT, Wilson RH, Meade AM, et al. Oxaliplatin and fluoropyrimidine chemotherapy plus or minus cetuximab: the effect of infusional 5-FU or capecitabine on the outcomes of theMRCCOIN trial in advanced colorectal cancer (ACRC). In: Proceedings of the American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium; 2010 July 13-20; Orlando, FL, Abstract nr 402.
    • (2010) Proceedings of the American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium
    • Maughan, T.S.1    Adams, R.2    Smith, C.G.3    Seymour, M.T.4    Wilson, R.H.5    Meade, A.M.6
  • 45
    • 84861432557 scopus 로고    scopus 로고
    • Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in firstline treatment of metastatic colorectal cancer: The NORDIC-VII study
    • Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in firstline treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012;30: 1755-62.
    • (2012) J Clin Oncol , vol.30 , pp. 1755-1762
    • Tveit, K.M.1    Guren, T.2    Glimelius, B.3    Pfeiffer, P.4    Sorbye, H.5    Pyrhonen, S.6
  • 46
    • 79956310674 scopus 로고    scopus 로고
    • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study
    • Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011;22: 1535-46.
    • (2011) Ann Oncol , vol.22 , pp. 1535-1546
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3    De Braud, F.4    Schuch, G.5    Zubel, A.6
  • 47
    • 84861382251 scopus 로고    scopus 로고
    • Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): Results of a multinational phase III trial (EFC10262-VELOUR)
    • (suppl abstr O-22: 9s (suppl ab0022)
    • Van Cutsem E, Tabernero J, Lakomy R, Prausova J, Ruff P, Van Hazel G, et al. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR). Ann Oncol 2011;22: 9s (suppl; abstr O-0022).
    • (2011) Ann Oncol , vol.22 , pp. 9
    • Van Cutsem, E.1    Tabernero, J.2    Lakomy, R.3    Prausova, J.4    Ruff, P.5    Van Hazel, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.